<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Short, intensive cycles of chemotherapy have resulted in improved survival in BurkittOs <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) in adults </plain></SENT>
<SENT sid="1" pm="."><plain>The prognosis of patients with <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV)-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is considered to be poor, but these patients have seldom been treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-specific protocols </plain></SENT>
<SENT sid="2" pm="."><plain>However, a study (PETHEMA-LAL3/97) in which patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> were treated regardless of their HIV status failed to find differences between HIV-infected and immunocompetent individuals </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, patients who received highly active antiretroviral therapy (HAART) seemed to have a slightly better disease-free survival than those who did not (p=0.051) </plain></SENT>
<SENT sid="4" pm="."><plain>We extended the follow-up analysis to elucidate the role of HAART in the survival of HIV-infected patients included in the PETHEMA-LAL3/97 protocol </plain></SENT>
</text></document>